You are unique, and your treatment should be too.

To learn more about Selective Internal Radiation Therapy (SIRT) for treating liver cancer and the unique benefits of our products, visit our patient information website.

Introducing Q-Suite™

Q-Suite™ is software for dosimetric verification of Ho-166 SIRT. A workflow-based user interface makes Q-Suite™ easy to learn and use.

Meet us in Stockholm at ECIO 2021

The Quirem team will attend ECIO in Stockholm from 11-14 April 2021

previous arrow
next arrow

SIRT in three steps

Quirem Medical develops and commercializes radioactive microspheres based on Holmium-166 for Selective Internal Radiation Therapy (SIRT). Holmium-166 microspheres can be visualized and quantified to improve patient selection, therapy planning and treatment verification. Through our innovative Holmium-166 platform technology, we aim to empower physicians to further drive treatment outcome of unresectable liver cancer after SIRT in three simple steps:


Select only those patients that are likely to benefit from SIRT. Use QuiremScout®,  a safe dose of holmium microspheres, to evaluate the biodistribution of particles prior to therapy in your patients.


Treat with QuiremSpheres®, the next-generation microspheres, indicated for treatment of unresectable liver tumors. Click here to learn what value QuiremSpheres® can bring to your clinic.


Use our software package Q-SuiteTM to determine SIRT succes right after the procedure, by evaluating the absorbed dose in the lesions and normal liver tissue

News and events

What our customers say


Zutphenseweg 55

7418AH Deventer

The Netherlands

Telephone: +31 85 0404170